1. Merck to buy Pandion for $1.9B for its immune modulators — Biden looking beyond Woodcock or Sharfstein for FDA commmisioner — Former AveXis execs launch gene therapy startup See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

Bonus is a JOKE here... Stay Away

Discussion in 'Aerie Pharma' started by anonymous, Nov 16, 2018 at 1:31 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Y'all drinking early on New Year's Eve!

  2. anonymous

    anonymous Guest

    Pick the the last Tinder smash you ghosted
  3. anonymous

    anonymous Guest

    What's being discussed about the sales force is not a pleasant thought right now. Many territories are not justifiable at this moment. The company will have to draw upon an additional line of credit just to launch Rocklatan.

    Get ready for a launch and then a big rollback in headcount around the middle of the year. The same territories that took off with Rho will take off with Rock (around 25-30 at the most). They don't have the cash to wait around until both products establish themselves.
  4. anonymous

    anonymous Guest

    Agreed. Time to start looking.